Bulk Anti-Cancer CAS 159351-69-6 Everolimus Raw Material Everolimus Powder Everolimus
HALAL ISO FDA 9 Inquiries
159351-69-6
Pharmaceutical Grade
0%
ZB
Boil Bag
2022-12-31
Herb Extracts,Cosmetic raw materails,API
-
Product Description
-
Seller Information
-
Inquiry History
-
Description
Product Name: Everolimus
CAS No.:159351-69-6
Molecular Formula: C53H83NO14
Molecular Weight: 958.22g/mol
Purity : 99%
Appearance: White Crystalline Powder
Typical use:Novel immunosuppressants
Standard Packing : 1gram,10gram,100gram
Shelf Life :2 years
Storage:Room temperature away from light
Everolimus is used to treat advanced (late-stage) cancers or noncancerous tumors, such as kidney and breast cancer, subependymal giant cell astrocytoma (SEGA, a brain tumor), renal angiomyolipoma (kidney tumor), and partial-onset seizures (epilepsy) with tuberous sclerosis complex (TSC), and neuroendocrine tumors of the pancreas, stomach or bowels, and lungs. It is used for patients who have already received other medicines that did not work well or those who will not be treated with surgery.
Everolimus works by interfering with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected, other unwanted effects will also occur. It belongs to the group of medicines known as antineoplastics (cancer medicines).
Everolimus is also used together with other medicines to lower the body's natural immunity in patients who receive kidney or liver transplants. When a patient receives an organ transplant, the body's white blood cells try to get rid of (reject) the transplanted organ. Everolimus works to suppress the immune system and prevents the white blood cells from getting rid of the transplanted organ.
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. 
CertificatesBasic Info-
Product Name:
Everolimus
Other Name:Rapamycin,42-O-(2-hydroxyethyl)-;23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine,rapamycin deriv.;42-O-(2-Hydroxyethyl)rapamycin;40-O-(2-Hydroxyethyl)rapamycin;SDZ-RAD;RAD 001;Everolimus;RAD;Certican;XIENCE V;Afinitor;Zortress;Xience;Afinitor Disperz;Votubia;1245613-55-1;2413306-61-1
CAS No.:159351-69-6
Molecular Formula:C53H83NO14
InChIKeys:InChIKey=HKVAMNSJSFKALM-GKUWKFKPSA-N
Molecular Weight:958.232
Exact Mass:958.22
EC Number:1806241-263-5
DSSTox ID:DTXSID0040599
HScode:29349990
Categories:
Characteristics-
PSA:
205 Ų
Density:1.18±0.1 g/cm3(Predicted)
Melting Point:No melting point
Boiling Point:998.7±75.0 °C(Predicted)
Flash Point:2℃
Refractive Index:1.548
Water Solubility:Soluble in dimethysulfoxide,ethanol and chloroform. Slightly soluble in water.
Storage Conditions:−20°C
Hazard IdentificationClassification of the substance or mixture
Specific target organ toxicity â repeated exposure, Category 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H372 Causes damage to organs through prolonged or repeated exposure
Precautionary statement(s) Prevention P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P319 Get medical help if you feel unwell.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Herb Extracts,Cosmetic raw materails,API
-
Location:
1403,Jinye B Block
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
8
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2015
-
-
Inquiry History9 Inquiries
Country Product Purchase Quantity Date Posted 
Spain
Factory Supply Everolimus 99% 159351-69-6 raw Everolimus Powder with Fast Delivery
1 MT Oct 5, 2023 
United States
Everolimus
25 G Jan 26, 2026 
Pakistan
Everolimus
1 KG Sep 26, 2025
Pakistan
Everolimus
1 G Nov 7, 2024 
India
Everolimus
25 G Jul 17, 2025 
Russia
Everolimus API
1 KG Jul 10, 2025 
United Kingdom
everolimus
1 KG Mar 22, 2025
India
Everolimus
15 G Sep 27, 2024
Spain
Everolimus 0,2% BHT
2 MT Dec 22, 2023 Post an enquiry for this product